Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management

BACKGROUND. Dysregulation of the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway is implicated in human cancer growth and progression. Agents targeting this pathway are associated with hyperglycemia due to interaction with the insulin-glucose regu...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncologist
Auteurs principaux: Khan, Khurum H., Wong, Mabel, Rihawi, Karim, Bodla, Shankar, Morganstein, Daniel, Banerji, Udai, Molife, Lulama R.
Format: Artigo
Langue:Inglês
Publié: AlphaMed Press 2016
Sujets:
New Drug Development and Clinical Pharmacology
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4943382/
https://ncbi.nlm.nih.gov/pubmed/27151652
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0248
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires